Paul Industries delivers passivation and derouging services for pharmaceutical manufacturers as a single-source supplier and installer. We design, fabricate, install, passivate, and validate passivation and derouging – restoring the corrosion-resistant passive layer on stainless process systems so they stay product-contact safe and audit-ready – built to the standards your process and your auditors require.
What pharmaceutical manufacturers need from passivation services
Pharmaceutical manufacturing lives and dies by cGMP compliance – FDA 21 CFR Parts 210/211, validated systems, and audit-ready documentation. Whether the process is oral solid dose, sterile injectables, or API synthesis, the utilities behind it (process water, clean steam, sanitary piping, CIP/SIP) have to be designed, installed, and documented to survive an FDA inspection.
For this work, that means cGMP (21 CFR 210/211) compliance, validated IQ/OQ/PQ turnover, USP-monograph water quality, and fully documented, traceable installations – not as an afterthought, but engineered in from the first drawing.
What we deliver
- Citric and nitric acid passivation to ASTM A967 / ASTM A380 on new and existing systems
- Field passivation of installed piping, tanks, and vessels – in place, without teardown
- Rouge identification and derouging for water systems and clean-steam lines
- Before/after testing (ferroxyl, water break, copper sulfate) and full documentation packages
- Restoration of the passive chromium-oxide layer to keep 316L corrosion-resistant and product-contact safe
One accountable partner
Most pharmaceutical projects get split between an equipment supplier and an install contractor – and the validation burden falls in the gap between them. Paul Industries closes that gap by self-performing the whole scope, from supply through documented turnover.
Related: Passivation Services services · Pharmaceutical Manufacturers solutions · Request a quote
Frequently asked questions
What passivation services do you provide for pharmaceutical companies?
What is needed varies sharply by dosage form, and quoting without establishing that is guesswork. Oral solid dose equipment, blenders, granulators and fluid bed units, is largely a shop and vessel exercise with moderate documentation. Parenteral manufacture raises the bar considerably, since rouge sheds particulate into an injectable product and the surfaces are compendial water and product contact. Active ingredient synthesis is closer to chemical processing, where solvent and reagent service makes alloy suitability the real question. We cover all three, but they are priced and scoped differently.
Why do pharmaceutical manufacturers need dedicated passivation?
Because 21 CFR 211.65 requires that equipment surfaces contacting components or drug product not be reactive, additive or absorptive in a way that alters product safety, identity, strength, quality or purity. A rouged or actively corroding stainless surface fails that test in two directions at once: it releases iron and other metals into the product stream, and its roughened condition holds residue and resists cleaning, which undermines the cleaning validation the same regulation expects. Passivation is how that requirement is met and, just as importantly, how it is evidenced.
Do you re-passivate rouged pharmaceutical water systems?
Yes, and on distribution loops the governing constraint is hydraulic rather than chemical. Chemistry has to move at sufficient velocity through every branch, point of use and sub-loop, not just the main run, and dead legs and zero-static valve bodies are exactly where rouge accumulates and exactly where flow is weakest. That usually means valves are cycled during the campaign and points of use opened in sequence rather than left closed. Loop derouging typically runs 10 to 36 dollars per linear foot for light oxide and 21 to 78 where it is adherent or embedded.
How do your passivation services support cGMP compliance?
By making the work an auditable, controlled activity rather than a maintenance task. On a qualified system, passivation is a change requiring assessment under change control, and the executed record needs to show chemistry, concentration, temperature, contact time, method, rinse-to-target evidence and post-treatment verification against a named acceptance test. The certificate scope must state which welds and sections were covered. Where the work follows a modification, it should reference the weld map for that modification, so an inspector can trace a specific joint to the treatment that covered it.
Do you passivate WFI and purified water loops for pharma?
Yes, and the loop detail that decides success is what happens at the points of use. During a passivation campaign each point of use needs to be opened and flowed so chemistry and then rinse water reach the valve body and the drop, because those short branches are where the film is weakest and where residue is most likely to remain. Rinsing has to continue to a measured conductivity or dissolved iron target rather than for a set time. Sanitization and a full sampling round follow before the loop returns to compendial service.
Which method do you use for pharmaceutical passivation, citric or nitric?
Both are ASTM A967-compliant. Citric is often chosen in pharma for lower hazard and easier in-situ handling inside occupied facilities; nitric is used where the specification or application calls for it. Paul Industries selects per alloy and system and documents it.
Can you passivate pharmaceutical equipment during a shutdown?
Yes, and pharmaceutical sites usually have a natural window already. Multi-product plants stop between campaigns for changeover cleaning, and annual maintenance shutdowns exist at most facilities, so passivation planned into one of those costs far less in lost production than a reactive campaign. The scheduling detail that gets missed is the tail: after the system returns to service it needs sanitization and a sampling round governed by laboratory incubation, and where the system supports aseptic production a media fill may be required before release.
Do you provide passivation for new pharmaceutical fabrication?
Yes. On new fabrication the useful additions are upstream of the chemistry. Material certification matters, because ASME BPE work requires tube and fittings with documented heat numbers traceable to mill certificates and those numbers belong on the weld map against each joint. Shop passivation of spools by immersion is cheaper per foot and more thorough than in-situ circulation, with better access and process control. What it cannot cover is the field welds joining those spools, so a final in-situ campaign after the last tie-in is still required.
How do you test passivation on pharmaceutical product-contact surfaces?
Product contact surfaces attract a higher evidentiary standard than utility pipework. Alongside an ASTM A967 acceptance test demonstrating that free iron has been removed, we recommend swab sampling of accessible contact surfaces analyzed for iron, rinse water analysis for dissolved iron and conductivity, and borescope documentation of the condition at defined locations. Where the surface feeds a parenteral process, particulate is a direct concern, so a visual standard for the rinse is worth defining in advance rather than judged by eye on the day.
What causes pharmaceutical stainless systems to rouge?
Five causes account for nearly all of it. Sustained high temperature, since oxidation rate rises steeply and hot Water for Injection and clean steam systems rouge fastest. Chlorides, which attack the passive film directly and arrive through feed water, cleaning chemistry or salt-bearing product streams. Mechanical damage from abrasive cleaning or cavitation that removes the film faster than it re-forms. Galvanic couples where a dissimilar metal component has been fitted. And inadequate initial passivation, particularly welds left untreated after a modification, which seeds oxide that then migrates downstream and deposits elsewhere.
Do you handle passivation waste safely inside a pharmaceutical plant?
Yes, and the plant-side questions matter more than the chemistry. Spent solution must not be routed to a drain that would disturb your wastewater permit limits or the biological treatment your site relies on, and nitrate or metal loading is exactly what a treatment works monitors. We establish the neutralization point, the discharge or manifest route and the effluent limits with your environmental group before mobilizing. Inside the building, hoses and pumps carry secondary containment and routes are planned so a spill cannot reach a drain serving a classified area.
Can you set up a re-passivation schedule for our pharmaceutical systems?
Yes, and the practical step is to put it inside your existing preventive maintenance and change control systems rather than tracking it separately. That means scheduled borescope inspection at named locations with baseline comparison, defined trigger values for dissolved iron, conductivity and total organic carbon that escalate to an engineering review, and a pre-approved protocol so a campaign can be executed against an existing change record instead of being written from scratch under time pressure. Facilities that do this schedule derouging into planned shutdowns; those that do not meet it as a deviation.
What standards do you passivate pharmaceutical equipment to?
ASTM A967 for the chemical treatment and its verification, ASTM A380 for cleaning and descaling of stainless steel equipment, and ASME BPE where the pipework is bioprocessing equipment carrying surface finish, drainability and documentation requirements. For pharmaceutical water specifically, USP general chapter 1231 on water for pharmaceutical purposes is the reference that frames why surface condition matters, since it addresses system design, sanitization and microbial control rather than only the monograph limits. Confirm which standard your quality organization expects to see named on the certificate.
Do you passivate pharmaceutical vessels, mixers, and transfer lines?
Yes, and each presents a different coverage problem. Vessels and mixers need chemistry to reach the whole internal surface including the underside of the head, behind baffles and around the agitator and its seal, which means the spray device pattern should be demonstrated by riboflavin coverage testing rather than assumed. Transfer lines need continuous fall to a drain point so solution and rinse actually clear, since a line that holds liquid holds residue. Flexible and demountable connections usually come out and are treated separately rather than left in circuit.
How much do pharmaceutical passivation services cost?
Passivation of new installed pipework typically runs 5 to 20 dollars per linear foot, and vessels, mixers and tanks 2,100 to 12,000 dollars each depending on volume and internals. Derouging an operating system is the more expensive job at roughly 10 to 36 dollars per linear foot for light surface oxide and 21 to 78 dollars where it is adherent or embedded and repeat cycles are required. Riboflavin spray coverage verification adds 4,800 to 22,000 dollars per vessel, and spent solution handling 3,500 to 22,000 dollars per campaign.
Can you passivate pharmaceutical systems nationwide?
Yes, and for manufacturers running several plants the value is consistency rather than coverage. Where each site engages a different contractor, procedures, acceptance criteria and certificate formats diverge, and a corporate quality group then has to reconcile them during an inspection. Working to one written procedure with the same control parameters, the same verification test and the same record format across sites removes that, and it makes trending comparable between plants. We mobilize from Kilmarnock, Virginia for planned work and confirm dates at quotation rather than claiming local presence we do not have.
What pharmaceutical requirements do you build to?
ASME BPE for process pipework, including SF4 electropolished surfaces where compendial water or drug product contact applies, USP monograph and general chapter requirements for Purified Water and Water for Injection, and 21 CFR 211 current good manufacturing practice for finished pharmaceuticals. Where product is supplied into Europe, EU GMP Annex 1 applies to sterile manufacture and is materially more prescriptive on contamination control strategy than its American counterpart. Which of these governs sets the surface finish, the acceptance test and the documentation, so establish it before specification rather than after.
Get a single-source quote
Paul Industries designs, fabricates, installs, passivates, and validates – one accountable partner instead of a vendor plus a contractor plus a validation firm. Tell us about your project and we will scope it.
Why does pharmaceutical stainless steel need passivation?
| Requirement | What it means |
|---|---|
| Purpose | Restore the chromium-rich passive layer destroyed by fabrication and welding |
| When required | After installation, after any weld, after mechanical work, and periodically thereafter |
| Standard | ASTM A967 for passivation; ASTM A380 for cleaning and descaling |
| Chemistry | Citric is the modern default; nitric still specified in some validated procedures |
| Pre-cleaning | Mandatory — passivating over grease, heat tint or weld scale achieves nothing |
| Coverage | Must be proven through the whole flow path, including branches and high points |
| Verification | Method stated before the work and result recorded |
| Consequence of skipping | Rouge, particulate, metal ion contamination and eventual product impact |
Do you handle validation, or just installation?
Both. For pharmaceutical systems the passivation record feeds directly into qualification rather than sitting beside it, so Paul Industries produces a package structured for that use: procedure, chemistry and concentration records, temperature and time logs, rinse water quality at endpoint, and acceptance testing to ASTM A967 with the test method and pass criterion stated. Calibration records for the conductivity meter and temperature probe are included, because uncalibrated instruments undermine every number in the package. Where the system is compendial we support the sanitization and sampling that follows, since a treated loop is not back in service until it has demonstrated quality at every point of use.
Can you take a project from design through startup?
Yes. On a pharmaceutical project the value of one contract is that passivation sits at a specific point in a longer sequence and cannot be moved. It must follow all welding, because any weld made afterwards destroys the film locally. It must precede sanitization and any qualification sampling. That places it near the end of a schedule already under pressure, which is when it is most often compressed, and a rinse cut short leaves acid in a dead leg that reappears later as a conductivity excursion. Holding design through startup together means that sequence is protected rather than negotiated between separate vendors.